Localization and expression of p27(KIP1) in multistage colorectal carcinogenesis

Cancer Research

Volumn 58, Issue 1, 1998, Pages 114-122

  Ciaparrone, Marco ^b   Yamamoto, Hirofumi ^c   Yao, Yao ^c   Sgambato, Alessandro ^b   Cattoretti, Giorgio ^c   Tomita, Naohiro ^d   Monden, Takushi ^d   Rotterdam, Heidrun ^c   Weinstein, I Bernard ^a,c  

^a Columbia University ^*  (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c New York Presbyterian Columbia University Medical Center   (United States)

^d OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; KI 67 ANTIGEN; MESSENGER RNA; PHOSPHOPROTEIN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; CANCER STAGING; CELL CYCLE; COLON CARCINOGENESIS; COLON MUCOSA; COLON POLYP; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE; CARCINOMA; CELL NUCLEUS; COLON TUMOR; FEMALE; INTESTINE MUCOSA; INTESTINE POLYP; MALE; METABOLISM; MIDDLE AGED; NORTHERN BLOTTING; RECTUM TUMOR; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARCINOMA; CDC2 PROTEIN KINASE; CELL CYCLE PROTEINS; CELL NUCLEUS; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; INTESTINAL POLYPS; KI-67 ANTIGEN; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; RECTAL NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 0031594186     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 79: 573-582, 1994
2. Hall, M., and Peters, G. Genetic alterations of cyclins, cyclin dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res., 68: 67-108, 1996.
3. Weinstein, I. B., and Zhou, P. Cell cycle control gene defects and human cancer. In: J. R. Bertino (ed.), Encyclopedia of Cancer, Vol. 1, pp. 256-267. New York: Academic Press, 1996.
4. Jiang, W., Zhang, Y-J., Kahn, S. M., Hollestein, M. C., Santella, R. M., Lu, S. H., Harris, C. C., Montesano, R., and Weinstein, I. B. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. USA, 90: 9026-9030, 1993.
5. Zhang, Y-J., Jiang, W., Chen, C. J., Lee, C. S., Kahn, S. M., Santella, R. M., and Weinstein, I. B. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 196: 1010-1016, 1993.
6. Gillett, C., Fantl, V., Smith, R., Fisher, C., Bartek, J., Dickson, C., Barnes, D., and Peters, G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res., 54: 1812-1817, 1994.
7. Bartkova, J., Lukas, J., Strauss, M., and Bartek, J. The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int. J. Cancer, 58: 568-573, 1994.
8. Arber, N., Hibshoosh, H., Moss, S. F., Sutter, T., Zhang, Y., Begg, M., Wang, S., Weinstein, I. B., and Holt, P. R. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology, 110: 669-674, 1996.
9. Keyomarsi, K., Conte, D., Jr., Toyofuku, W., and Fox, M. P. Deregulation of cyclin E in breast cancer. Oncogene. 11: 941-950, 1995.
10. Khatib, Z. A., Matsushime, H., Valentine, M., Shapiro, D. N., Sherr, C. J., and Look, A. T. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res., 53: 5535-5541, 1993.
11. Zhang, T., Nanney, L. B., Luongo, C., Lamps, L., Heppner, K. J., DuBois, R. N., and Beauchamp, R. D. Concurrent overexpression of cyclin D1 and cyclin-dependant kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia mice and human familial adenomatous polyposis patients. Cancer Res., 57: 169-175, 1997.
12. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
13. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.), 371: 257-261, 1994.
14. INK4/MTS2-related CDK6 inhibitor, correlates with wild-type Rb function. Genes Dev., 8: 2939-2952, 1994.
15. Hirai, H., Roussel, M. F., Kato, J., Ashmun, R. A., and Sherr, C. J. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol., 15: 2672-2681, 1995.
16. Tam, S. W., Shay, J. W., and Pagano, M. Differential expression and cell cycle regulation of the cyclin dependent kinase 4 inhibitor p16/INK4. Cancer Res., 54: 5816-5820, 1994.
17. Jin, X., Nguyen, D., Zhang, D., Kyritsis, A. P., and Roth, J. A. Cell cycle arrest and inhibition of tumor cell proliferation by the p16/INK4 gene mediated by an adenovirus vector. Cancer Res., 55: 3250-3253, 1995.
18. Reed, J. A., Loganzo, F. j., Shea, C. R., Walker, G. J., Flores, J. F., Glendening, J. M., Bogdany, J. K., Shiel, M. J., Haluska, F. J., and Fountain, J. W. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res., 55: 2713-2718, 1995.
19. Sill, H., Goldman, J. M., and Cross, N. Homozygous deletions of the p16 tumor suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood, 85: 2013-2016, 1995.
20. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H. J., Tucker, M. A., and Dracopoli, N. M. Germline p16 mutations in familial melanoma. Nat. Genet., 8: 15-21, 1994.
21. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
22. Serrano, M., Lee, H-W., Chin, L., Cordon-Cardo, C., Beach, D., and R. A., D. Role of the INK4a locus in tumor suppression and cell mortality. Cell, 85: 27-37, 1996.
23. Xiong, Y., Hannon, G. J., Zhang, G. J., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
24. 1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
25. KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
26. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
27. Kip2, a structurally distinct member of the Cip1 cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev., 9: 650-662, 1995.
28. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75: 817-825, 1993.
29. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Induction of WAF1/CIP by a p53 independent pathway. Cancer Res., 54: 3391-3395, 1994.
30. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., and Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 211: 90-98, 1994.
31. Shiohara, M., El-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D-L., Vogelstein, B., and Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
32. 1 checkpoint control. Cell, 82: 675-684, 1995.
33. Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., and Hannon, G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (Lond.), 377: 552-557, 1995.
34. 1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
35. KIP1) of cyclin-dependent kinase 4 activation. Cell, 79: 487-496, 1994.
36. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (Lond.), 372: 570-573, 1994.
37. Kip1 in γ interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. Oncogene. 14: 2111-2122, 1997.
38. Kip1 in a human gastric cell line. Cell Growth Differ., 8: 47-52, 1997.
39. Kip1 by cDNA antisense suppresses quiescence (Go state) in fibroblasts. J. Biol. Chem., 271: 18337-18341, 1996.
40. Kranenburg, O., Scharnhorst, V., Van der Eb, A., and Zantema, A. Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. J. Cell Biol., 131: 227-234, 1995.
41. Kip1 accumulation during the cell cycle. Science (Washington DC), 271: 1861-1864, 1996.
42. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Washington DC), 269: 682-685, 1995.
43. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res., 55: 1206-1210, 1995.
44. Kip1, to regions involved in human cancer. Cancer Res., 55: 1199-1205, 1995.
45. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res., 55: 1211-1214, 1995.
46. Doki, D., Imoto, M., Han, E. K-H., Sgambato, A., and Weinstein, I. B. Correlations between the levels of expression of cyclin D1 and other cell cycle-related genes in human esophageal cancer cell lines. Carcinogenesis (Lond.), 18: 1139-1148, 1997.
47. Kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ., 7: 699-710, 1996.
48. Kip1. Cancer Res., 56: 1389-1399, 1996.
49. Kip1 expression. Cell Growth Differ., 8: 393-405, 1997.
50. Kip1 in Human Breast Cancers. Clin. Cancer Res., 3: 1879-1887, 1997.
51. Zhou, P., Jiang, W., Zhang, Y., Kahn, S. M., Schieren, I., Santella, R. M., and Weinstein, I. B. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene, 11: 571-580, 1995.
52. Arber, N., Doki, Y., Han, E. K-H., Sgambato, A., Zhou, P., Kim, N., Delohery, T., Klein, M. G., Holt, P. R., and Weinstein, I. B. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res., 57: 1569-1574, 1997.
53. Gerdes, J., Schwab, U., Lenke, H., and Stein, H. Production of a monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer, 31: 13-20, 1983.
54. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Florentino, M., Draetta, G. F., Jessup, G. M., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
55. Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
56. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
57. Johnston, P. G., O'Brien, M. J., Dervan, P. A., and Carney, D. N. Immunohistochemical analysis of cell kinetic parameters in colonic adenocarcinomas, adenomas, and normal mucosa. Hum. Pathol., 7: 696-700, 1989.
58. Han, E. K., Sgambato, A., Jiang, W., Zhang, Y., Santella, R. M., Doki, Y., Cacace, A. M., Schieren, I., and Weinstein, I. B. Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene, 10: 953-962, 1995.
59. Zhar, J. H. Biostatistical Analysis. Englewood Cliffs, NJ: Prentice-Hall, Inc., 1974.
60. Kip1 and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA, 94: 6380-6385, 1997.
61. Esposito, V., Baldi, A., De Luca, A., Groger, A. M., Loda, M., Giordano, G. G., Caputi, M., Baldi, F., Pagano, M., and Giordano, A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res., 57: 3381-3385, 1997.
62. Polyak, K., Hamilton, S. R., Vogelstein, B., and Kinsler, K. W. Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. Am. J. Pathol., 149: 381-387, 1996.
63. WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J. Pathol., 179: 248-253, 1996.
64. CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation. Int. J. Cancer, 69: 259-264, 1996.
65. WAF1/CIP1SDI1 and p53 proteins in formalin-fixed, paraffin-embedded tissue sections of colorectal carcinoma. Hum. Pathol., 27: 912-916, 1996.
66. MST1 gene status jn human esophageal carcinoma cell lines. J. Exp. Ther. Oncol., 1: 7-12, 1996.
67. WAF1 immunohistochemical expression in breast carcinomas: correlations with clinicopathological data, oestrogen receptor status MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br. J. Cancer, 74: 208-215, 1996.
68. LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., and Harlow, E. New functional activities for the p21 family of CDK inhibitors. Genes Dev., 11: 847-862, 1997.
69. Kip1. Cell, 85: 721-732, 1996.
70. Kip1-deficiem mice. Cell, 85: 733-744, 1996.
71. Kip1 in the in vitro differentiation of murine keratinocytes. Cell Growth Differ., 8: 203-211, 1997.